Loading…
Loading…
if you could try to help do some math for us on the call as it relates to the headwind this quarter from selling weeks
I just wanted to clarify on the selling weeks. We have that dynamic at like close to an 11% sequential headwind
can you talk a little bit more about the criteria physicians are using
there are certain physicians who they actually can use the drug without going through a PNT committee. Any metrics there
are you expecting the average insurer to cross manage between Part B and Part D
how are you at least qualitatively right now thinking about synergies and leveraging existing capabilities
How should we think about the commercial implications if these studies are positive
do you feel like you can get back to sustainable revenue growth based on what you have internally and what you have high visibility into?